Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

DOI: 10.1158/1078-0432.CCR-07-0869 Published September 2007

Online Impact

Volume 13, Issue 17, pp. 5144-5149

DOI

PubMed

Published By

Print ISSN

Online ISSN

History

American Association for Cancer Research

Authors' Affiliations:¹Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and ²Clinical Center, NIH, Bethesda, Maryland; ³Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma; ⁴Department of Medicine, University of Chicago, Chicago, Illinois; and ⁵Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Requests for reprints:
Raffit Hassan, Laboratory of Molecular Biology, National Cancer Institute, Room 5116, 37 Convent Drive, Bethesda, MD 20892-4264. Phone: 301-451-8742; Fax: 301-402-1344; E-mail: hassanr{at}mail.nih.gov.